We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

94 hedge funds and large institutions have $226M invested in Marinus Pharmaceuticals, Inc in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 7

111% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 18

72% more capital invested

Capital invested by funds: $131M → $226M (+$94.9M)

27% more funds holding

Funds holding: 74 → 94 (+20)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

42% less call options, than puts

Call options by funds: $819K | Put options by funds: $1.41M

Holders
94
Holders Change
+20
Holders Change %
+27.03%
% of All Funds
1.93%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
27
Increased
38
Reduced
18
Closed
7
Calls
$819K
Puts
$1.41M
Net Calls
-$593K
Net Calls Change
+$414K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$13.2M
2
BC
Boxer Capital
California
+$11M
3
LPC
Lion Point Capital
New York
+$10.3M
4
SCM
Suvretta Capital Management
New York
+$4.6M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.45M

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$2.11M
2
VA
VR Adviser
New York
-$1.79M
3
N
Nuveen
North Carolina
-$708K
4
ACM
Asymmetry Capital Management
California
-$619K
5
JP Morgan Chase
JP Morgan Chase
New York
-$611K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$1.21M +$1.09M +118,574 New
Victory Capital Management
27
Victory Capital Management
Texas
$1.07M +$911K +99,070 +1,534%
Goldman Sachs
28
Goldman Sachs
New York
$974K +$745K +80,950 +544%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$832K -$309K -33,580 -29%
N
30
Nuveen
North Carolina
$773K -$708K -76,939 -50%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$627K +$20.3K +2,209 +4%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$609K +$368K +40,027 +201%
Charles Schwab
33
Charles Schwab
California
$521K +$18.9K +2,060 +4%
Los Angeles Capital Management
34
Los Angeles Capital Management
California
$520K +$195K +21,231 +71%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$477K +$431K +46,908 New
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$417K -$52K -5,650 -12%
VEA
37
Virtus ETF Advisers
New York
$372K +$337K +36,640 New
Two Sigma Advisers
38
Two Sigma Advisers
New York
$324K +$266K +28,875 +947%
PAI
39
Palo Alto Investors
California
$318K – – –
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$317K – – –
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$267K +$72K +7,831 +42%
PA
42
Parallel Advisors
California
$266K +$241K +26,245 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$265K +$118K +12,850 +97%
Wells Fargo
44
Wells Fargo
California
$256K +$95.9K +10,425 +71%
EGM
45
Engineers Gate Manager
New York
$255K +$231K +25,132 New
PHP
46
Parkman Healthcare Partners
Connecticut
$254K +$230K +25,000 New
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$188K +$110K +12,000 +183%
UBS Group
48
UBS Group
Switzerland
$144K -$27.1K -2,947 -17%
CM
49
Caption Management
Oklahoma
$142K – – –
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$133K +$8.29K +901 +7%
1
2
3 4

MRNS Hedge Fund Activity: Q2 2020 in Review

94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2020, worth a combined $226M — up 72% from $131M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new MRNS positions and 7 closed out — a net gain of 20 holders — while 38 added to existing stakes and 18 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $13.2M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $2.11M sold.

  • 94 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2020, up from 74 in Q1 2020.
  • Funds reported $226M of Marinus Pharmaceuticals, Inc stock for Q2 2020, up 72% quarter-over-quarter.
  • 27 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2020 and 7 closed out, a net change of +20 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q2 2020 was Avoro Capital Advisors, an estimated $13.2M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q2 2020 was Acuta Capital Partners, an estimated $2.11M sold.

Based on aggregated 13F filings for Q2 2020.